[177Lu]Lu-PSMA-617 (PluvictoTM): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
[177Lu]Lu-PSMA-617 (PluvictoTM): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer
Authors
Keywords
-
Journal
Pharmaceuticals
Volume 15, Issue 10, Pages 1292
Publisher
MDPI AG
Online
2022-10-21
DOI
10.3390/ph15101292
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Dosimetry of 177Lu-PSMA-617 for the treatment of metastatic castration-resistant prostate cancer: results from the VISION trial sub-study.
- (2022) Ken Herrmann et al. JOURNAL OF CLINICAL ONCOLOGY
- Application of Cleavable Linkers to Improve Therapeutic Index of Radioligand Therapies
- (2022) Joseph Lau et al. MOLECULES
- [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial
- (2021) Michael S Hofman et al. LANCET
- PSMA-Radioligandentherapie könnte Nuklearmedizin vor infrastrukturelle Herausforderungen stellen: Ergebnisse einer Basiskalkulation zur Kapazitätsplanung nuklearmedizinischer Betten im deutschen Krankenhaussektor
- (2021) Claus Zippel et al. NUKLEARMEDIZIN-NUCLEAR MEDICINE
- Challenges and future options for the production of lutetium-177
- (2021) W. V. Vogel et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Nuclear Medicine beyond VISION
- (2021) Wolfgang Peter Fendler et al. JOURNAL OF NUCLEAR MEDICINE
- 177 Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: Initial 254-patient results from a prospective registry (REALITY Study)
- (2021) Fadi Khreish et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Intra-therapeutic dosimetry of [177Lu]Lu-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer patients and correlation with treatment outcome
- (2021) Steffie M. B. Peters et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports
- (2021) M. J. M. Uijen et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with 177Lu-PSMA-617 for metastatic Castration-reSISTant Prostate Cancer (RESIST-PC): Efficacy results of the UCLA cohort
- (2021) Jeremie Calais et al. JOURNAL OF NUCLEAR MEDICINE
- Safety of PSMA-targeted molecular radioligand therapy with 177Lu-PSMA-617: results from the prospective multicenter phase 2 trial RESIST-PC NCT03042312
- (2021) Jeremie Calais et al. JOURNAL OF NUCLEAR MEDICINE
- Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
- (2021) Oliver Sartor et al. NEW ENGLAND JOURNAL OF MEDICINE
- The salivary glands as a dose limiting organ of PSMA- targeted radionuclide therapy: A review of the lessons learnt so far
- (2021) Nathalie Heynickx et al. NUCLEAR MEDICINE AND BIOLOGY
- [68Ga]Ga-PSMA-11: The First FDA-Approved 68Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer
- (2021) Ute Hennrich et al. Pharmaceuticals
- 177Lu-PSMA-617 versus docetaxel in chemotherapy-naïve metastatic castration-resistant prostate cancer: a randomized, controlled, phase 2 non-inferiority trial
- (2021) Swayamjeet Satapathy et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Prostate-specific membrane antigen radioligand therapy using 177Lu-PSMA I&T and 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: comparison of safety, biodistribution and dosimetry
- (2021) Christiane Schuchardt et al. JOURNAL OF NUCLEAR MEDICINE
- Early PSA Change after [177Lu]PSMA-617 Radioligand Therapy as a Predicator of Biochemical Response and Overall Survival
- (2021) Felix Kind et al. Cancers
- Expanding Theranostic Radiopharmaceuticals for Tumor Diagnosis and Therapy
- (2021) Cristina Barca et al. Pharmaceuticals
- Radioligand therapy using [177Lu]Lu-PSMA-617 in mCRPC: a pre-VISION single-center analysis
- (2020) Robert Seifert et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [177Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial)
- (2020) Hojjat Ahmadzadehfar et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Atomic Nanogenerators in Targeted Alpha Therapies: Curie’s Legacy in Modern Cancer Management
- (2020) Mareike Roscher et al. Pharmaceuticals
- Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA
- (2020) Benedikt Feuerecker et al. EUROPEAN UROLOGY
- Renal outcomes of radioligand therapy: experience of 177lutetium—prostate-specific membrane antigen ligand therapy in metastatic castrate-resistant prostate cancer
- (2019) Marat Gallyamov et al. Clinical Kidney Journal
- Long term follow-up and outcomes of re-treatment in an expanded 50 patient single-center phase II prospective trial of Lutetium-177 (177Lu) PSMA-617 theranostics in metastatic castrate-resistant prostate cancer
- (2019) John Violet et al. JOURNAL OF NUCLEAR MEDICINE
- Multidose formulation of ready-to-use 177 Lu-PSMA-617 in a centralized radiopharmacy set-up
- (2018) Sudipta Chakraborty et al. APPLIED RADIATION AND ISOTOPES
- [ 177 Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
- (2018) Michael S Hofman et al. LANCET ONCOLOGY
- External radiation exposure, excretion, and effective half-life in 177Lu-PSMA-targeted therapies
- (2018) J. Kurth et al. EJNMMI Research
- Metastatic Prostate Cancer With Restored Hormone-Response After Radioligand Therapy With 177Lu-PSMA-617
- (2016) Carl Diedrich Schlenkhoff et al. CLINICAL NUCLEAR MEDICINE
- Prospects of medium specific activity177Lu in targeted therapy of prostate cancer using177Lu-labeled PSMA inhibitor
- (2016) Sudipta Chakraborty et al. JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS
- Linker Modification Strategies To Control the Prostate-Specific Membrane Antigen (PSMA)-Targeting and Pharmacokinetic Properties of DOTA-Conjugated PSMA Inhibitors
- (2016) Martina Benešová et al. JOURNAL OF MEDICINAL CHEMISTRY
- PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617
- (2016) C. Kratochwil et al. JOURNAL OF NUCLEAR MEDICINE
- The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions
- (2015) A. Afshar-Oromieh et al. JOURNAL OF NUCLEAR MEDICINE
- Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer
- (2015) M. Bene ova et al. JOURNAL OF NUCLEAR MEDICINE
- Interactions between Human Glutamate Carboxypeptidase II and Urea-Based Inhibitors: Structural Characterization†
- (2008) Cyril Barinka et al. JOURNAL OF MEDICINAL CHEMISTRY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now